Mayo Clinic laboratory and pathology research roundup: April 27

By Samantha Rossi • April 27, 2021

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

The CLL-international prognostic index (CLL-IPI) predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.

The utility of the chronic lymphocytic leukemia - international prognostic index (CLL-IPI) in predicting outcomes of individuals with Rai 0 stage CLL and monoclonal B-cell lymphocytosis (MBL) is unclear. We identified 969 individuals (415 MBL and 554 Rai 0 CLL; median age=64 years, 65% men) seen at Mayo Clinic between 1/1/2001 and 10/1/2018, and ascertained time to first therapy (TTFT) and overall survival (OS). After a median follow up of 7 years, the risk of disease progression needing therapy was 2.9%/year for MBL (median=not reached) and 5%/year for Rai 0 CLL (median=10.4 years). Among patients with low, intermediate and high/very high risk CLL-IPI risk groups, the estimated 5-year risk of TTFT was 13.5%, 30%, and 58%, respectively, p<0.0001 (c-statistic=0.69); and the estimated 5-year OS was 96.3%, 91.5%, and 76%, respectively, p<0.0001 (c-statistic:0.65). In a multivariable analysis of absolute B-cell count with individual factors of the CLL-IPI, the absolute B-cell count was associated with shorter TTFT (hazard ratio [HR] for each 10 x 109/L increase: 1.31; p<0.0001), and shorter OS (HR: 1.1; p=0.02). The OS of the entire cohort was similar to age- and sex-matched general population of Minnesota (p=0.17), although Rai 0 CLL patients with high and very high risk CLL-IPI score had significantly shorter OS (p=0.01, and p=0.0001, respectively). The results of this study demonstrate the ability of CLL-IPI to predict time from diagnosis to first treatment (an endpoint not impacted by therapy) in a large cohort of patients whose only manifestation of disease is a circulating clonal lymphocyte population. Via Blood.

Read more.

Published to PubMed This Week

• Return-to-play guidelines for athletes after COVID-19 infection.
  JAMA Cardiology
• High-sensitivity cardiac troponin t for the detection of myocardial injury and risk stratification in COVID-19.
  Clinical Chemistry
• Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett's esophagus in a multi-site case-control study.
  Gastrointestinal Endoscopy
• Ocular relapse of b-cell acute lymphoblastic leukemia.
  JAMA Ophthalmology
• IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.
  Blood Advances
• PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
  Gynecologic Oncology
• Correction for Mathison et al., "Medical Parasitology Taxonomy Update, January 2018 to May 2020".
  Journal of Clinical Microbiology
• Surface color spectrophotometry in a murine model of steatosis: an accurate technique with potential applicability in liver procurement.
  Lab Investments
• Hydrogen peroxide-producing electrochemical bandage controlled by a wearable potentiostat for treatment of wound infections.
  Biotechnology and Bioengineering
• Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China.
  Journal of Cancer

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.